POZEN, Inc. (NASDAQ:POZN)

CAPS Rating: 3 out of 5

A pharmaceutical company focused on developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions.

Results 1 - 20 of 34 : 1 2 Next »

Recs

0
Member Avatar wstanislaw (53.42) Submitted: 7/16/2015 6:21:57 PM : Outperform Start Price: $11.34 POZN Score: +3.12

Pozen pharmaceuticals - Specialties in pain management, marketing a non nsaid / non opiate pain relief among other drugs. Acquired an Irish company and will be relocating there - windfall of 12.5% Irish tax rate vs 30-40% us. Inconsistent drug pipeline needs watching. FDA okays coming soon? Also management change from development to sales in 2015 - effectiveness bears watching.

Recs

0
Member Avatar manirg (96.00) Submitted: 12/1/2014 10:28:17 AM : Outperform Start Price: $7.46 POZN Score: +52.39

undervalued

Recs

0
Member Avatar genedom (98.49) Submitted: 3/10/2014 3:32:41 AM : Outperform Start Price: $8.23 POZN Score: +28.97

A undervalue stock ready to fly high.

Recs

1
Member Avatar line70day (< 20) Submitted: 12/11/2013 9:25:08 AM : Outperform Start Price: $7.15 POZN Score: +45.86

Aquired US rights to arthritis treatment Vimovo from Asta Zeneca Surged 32% it will recieve a 10% royalty from Horizon as part of the deal. Horizan with a full-year rev. in the range of $190 M - $205 M

Recs

0
Member Avatar kato (< 20) Submitted: 12/8/2013 11:35:53 AM : Outperform Start Price: $6.56 POZN Score: +60.80

strong cash position and excellent growth rate

Recs

0
Member Avatar Mary953 (85.31) Submitted: 11/10/2013 2:50:27 PM : Outperform Start Price: $4.64 POZN Score: +131.26

Nov 5 blog makes me think this is a possibility, not to bet a huge amount on, but definitely for a small gamble. As in, don't purchase with money that you cannot afford to lose.
A non-NSAID, non-opiad pain reliever would be huge.

Recs

0
Member Avatar kulls81 (< 20) Submitted: 11/29/2012 1:07:43 PM : Outperform Start Price: $4.30 POZN Score: +121.71

Magic Formula 11-29-12

Recs

0
Member Avatar ChrisMcLong (< 20) Submitted: 5/18/2012 10:51:11 AM : Outperform Start Price: $5.34 POZN Score: +57.17

when the FDA approves it.

Recs

0
Member Avatar eesirrius (35.46) Submitted: 7/15/2011 10:29:18 AM : Outperform Start Price: $3.73 POZN Score: +150.25

MFI Screen

Recs

1
Member Avatar valuefocusgroup (21.95) Submitted: 4/5/2011 9:30:30 AM : Outperform Start Price: $4.62 POZN Score: +92.82

Price/earnings of 7.50, market cap of 170.45 million, Debt/equity of zero, Return on Invested Capital (TTM) of 48.89, based in North Carolina, United States, focus on acute pain treatment.

Recs

5
Member Avatar pbtoau78 (79.94) Submitted: 5/12/2010 2:08:58 PM : Underperform Start Price: $6.74 POZN Score: +7.58

This is a classic example of a false moat. Building off zzlangerhans' example of treximet, Vimovo which is falsely being labeled as a "pain drug" (NSAIDs are fundamentally anti-inflammatory drugs- which secondarily may reduce pain levels) is a combination of naproxen and "immediate" acting omeprazole. Nexium (omeprazole) will be going generic in 2-3 years and naproxen is cheap and efficacious in it's generic form. Can someone tell me why I woulded just prescribe daily prilosec or a H2 blocker like ranitidine and generic naproxen instead of an expensive marketed (combo). Longs maybe you can address why I, as a practioner, would chose this product instead? POZN is producing illogical, impractical products thusfar. I hold no real life position, but am short long term in CAPs.

Recs

0
Member Avatar drobuck340 (< 20) Submitted: 4/29/2010 12:16:04 AM : Outperform Start Price: $8.97 POZN Score: -45.87

great stock

Recs

0
Member Avatar LonWa (< 20) Submitted: 4/2/2010 1:40:33 PM : Outperform Start Price: $8.31 POZN Score: -38.33

FDA approval just around the corner for new product, look for approval on or after April 30 of this year.

Recs

0
Member Avatar JesusForgives (78.88) Submitted: 4/1/2010 5:51:04 AM : Outperform Start Price: $7.87 POZN Score: -31.35

Personally, i think this is a great stock to do a put option on for may10 because its waiting on a FDA approval that can take time but for the short term to turn profits i would!

Recs

0
Member Avatar philsie2 (< 20) Submitted: 12/8/2008 12:06:05 AM : Outperform Start Price: $5.15 POZN Score: -13.84

If FDA accepts the gastric ulcer endpoint for PN400 and the PA program then we'll see a very strong move back to the $12-15. Add to that a very good acceptance, so far, of Treximet there are a lots of positives in the making. Excellent time to take advantage of a good entry; though right now that's true of just about anything.

Recs

0
Member Avatar markwusinich (< 20) Submitted: 8/20/2008 8:55:57 AM : Outperform Start Price: $9.65 POZN Score: -50.30

Top 20 Naked Put Trades

Recs

0
Member Avatar philsie1 (< 20) Submitted: 7/7/2008 1:33:56 PM : Outperform Start Price: $7.83 POZN Score: -26.66

Undervalued per earnings potential of Treximet and pipeline including PN and PA. Many catalysts coming in next couple months, sales data on Treximet, partner for PA and SPA acceptance. PN data later in year or early next year.

Recs

0
Member Avatar corkymilb (< 20) Submitted: 7/6/2008 11:27:28 AM : Outperform Start Price: $8.23 POZN Score: -30.20

effective drug with a lot of GSK marketing behind it.

Recs

0
Member Avatar zoiebelle (67.11) Submitted: 6/4/2008 9:30:21 PM : Outperform Start Price: $11.32 POZN Score: -54.77

medical treatment process technology breakthrough.

Recs

4
Member Avatar everclear08 (< 20) Submitted: 3/14/2008 11:11:14 AM : Outperform Start Price: $8.57 POZN Score: -33.28

FDA concerns about tox have been addressed according to publicly available data. Given that the concern was addressed and seemingly negated, it would seem approval is right around the corner.

Word of Caution: You can never predict how the FDA will react. I recall a legal case I did some research on involving BMS a few years back where BMS hyping product and the whole world thought was a "gimme" only to have it rejected. remember, only the FDA knows what the FDA is thinking... though sometimes i not even sure they know exactly what they are thinking!

Assuming approval is granted, parntership with GSK is a HUGE bonus. GSK sales force has experience in this therapeutic area. Easy transition, easy ins with current trusted physicians... assuming no negative stories come up in post marketing surviellence look for this stock to rise signficantly from current prices. Good news is these prices are a steal with the pps taking a beating, probably due it being a speculative stock and big investors cashing out trying to meet margin calls elsewhere.

pain is huge area in healthcare, but can be a bit risky as well. however, from the data i've seen i think there is promise in the product. beyond a few years i have my doubts on the leadership of the company, but in a few years who knows what will be and i'll reevaluate....

Results 1 - 20 of 34 : 1 2 Next »

Featured Broker Partners


Advertisement